Atypische Neuroleptika und metabolisches Syndrom
- 作者Andreas Baranyi; Renè Yazdani; Alexandra Haas-Krammer; Alexandra Stepan; Hans-Peter Kapfhammer; Hans-Bernd Rothenhäusler
- 卷第157卷
- 印刷ISSN0043-5341
- 电子ISSN1563-258X
- 文件大小290.10KB
- 发表时间2007-06
- DOI10.1007/s10354-007-0379-9
- 页码255-270
Short interfering RNA (siRNA): tool or therapeutic?Cejka, Daniel; Losert, Doris; Wacheck, Volker · Clinical Science · 2006
Strategies for designing clinical trials for oligonucleotide therapeuticsVolker Wacheck · 2004
mTOR pathway inhibitors in cancer therapy: moving past rapamycinWacheck, Volker · Pharmacogenomics · 2010
Farnesyl Thiosalicylic Acid Chemosensitizes Human Melanoma In VivoHalaschek-Wiener, Julius; Kloog, Yoel; Wacheck, Volker; Jansen, Burkhard · Journal of Investigative Dermatology · 2003
Targeting sphingosine kinase 1 with LNA oligonucleotides in gastric cancerThorsten Füreder; Doris Hoeflmayer; Bo Hansen; Volker Wacheck · 2008
Bcl-xL Antisense Oligonucleotides Chemosensitize Human Glioblastoma CellsGuensberg, Patrick; Wacheck, Volker; Lucas, Trevor; Monia, Brett; Pehamberger, Hubert; Eichler, Hans-Georg; Jansen, Burkhard · Chemotherapy · 2002
Synthesis and cytotoxic activity of resveratrol-based compoundsNorbert Handler; Philipp Saiko; Walter Jaeger; Thomas Szekeres; Volker Wacheck; Heinz Berner; Klaus Leisser; Thomas Erker · 2008